220 related articles for article (PubMed ID: 26096845)
1. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract][Full Text] [Related]
2. Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.
Wei W; Birrer MJ
Cancer Cell; 2015 Jul; 28(1):7-9. PubMed ID: 26175410
[TBL] [Abstract][Full Text] [Related]
3. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract][Full Text] [Related]
4. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
5. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
[No Abstract] [Full Text] [Related]
7. Activation of spleen tyrosine kinase (Syk) at fertilization in Rhinella arenarum eggs.
Mouguelar VS; Coux G
Int J Dev Biol; 2014; 58(10-12):811-8. PubMed ID: 26154322
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
9. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
10. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
11. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
12. Syk-dependent phosphorylation of microtubules in activated B-lymphocytes.
Faruki S; Geahlen RL; Asai DJ
J Cell Sci; 2000 Jul; 113 ( Pt 14)():2557-65. PubMed ID: 10862713
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.
Kuiatse I; Baladandayuthapani V; Lin HY; Thomas SK; Bjorklund CC; Weber DM; Wang M; Shah JJ; Zhang XD; Jones RJ; Ansell SM; Yang G; Treon SP; Orlowski RZ
Clin Cancer Res; 2015 Jun; 21(11):2538-45. PubMed ID: 25748087
[TBL] [Abstract][Full Text] [Related]
14. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.
Zheng Y; Sethi R; Mangala LS; Taylor C; Goldsmith J; Wang M; Masuda K; Carrami EM; Mannion D; Miranda F; Herrero-Gonzalez S; Hellner K; Chen F; Alsaadi A; Albukhari A; Fotso DC; Yau C; Jiang D; Pradeep S; Rodriguez-Aguayo C; Lopez-Berestein G; Knapp S; Gray NS; Campo L; Myers KA; Dhar S; Ferguson D; Bast RC; Sood AK; von Delft F; Ahmed AA
Nat Commun; 2018 Feb; 9(1):476. PubMed ID: 29396402
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase mediates high glucose-induced transforming growth factor-β1 up-regulation in proximal tubular epithelial cells.
Yang WS; Chang JW; Han NJ; Lee SK; Park SK
Exp Cell Res; 2012 Sep; 318(15):1867-76. PubMed ID: 22659134
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
17. Proteomic and genetic approaches identify Syk as an AML target.
Hahn CK; Berchuck JE; Ross KN; Kakoza RM; Clauser K; Schinzel AC; Ross L; Galinsky I; Davis TN; Silver SJ; Root DE; Stone RM; DeAngelo DJ; Carroll M; Hahn WC; Carr SA; Golub TR; Kung AL; Stegmaier K
Cancer Cell; 2009 Oct; 16(4):281-94. PubMed ID: 19800574
[TBL] [Abstract][Full Text] [Related]
18. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Bourgne C; Janel A; Berger J; Rapatel C; Tournilhac O; Hermet E; Guerci A; Lioret F; Briançon A; Bamdad M; Boiret-Dupré N; Berger MG
Leuk Res; 2015 Mar; 39(3):329-34. PubMed ID: 25612940
[TBL] [Abstract][Full Text] [Related]
20. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]